Sarepta Therapeutics, Inc.

Joyant Pharmaceuticals, Inc.

Becton Dickinson and Company Limited

The University of Texas System

Baylor University

Massachusetts Institute of Technology

Ming Zhou

Gunnar J Hanson

Qi Wei

Charles G Caldwell

Dwight D Weller

Susan Harran

Bao Zhong Cai

Jonathan Karl Burkholz

Siddarth K Shevgoor

Yiping Ma

Lai Wang

Weston F Harding

Bryan Fred Bihlmaier

Robert Magnusson

Bradley Lether Pentelute

Huibin Liu

Patrick G Harran

Janice Lin

Xiaoming Xu

Alexander Charles Rudolph

Theresa J Hermel-Davidock

Kevin G Pinney

Marc Weimer

Mark David Simon

Mary Lynn Trawick

Haizhou Sun

Hong Zong

J Freeland Ackley

Martin Pomerantz

Georgeanne Purvinis

Purnomo Priambodo

Theresa A Maldonado

Wara Milenka Arispe-Angulo

Shen-En Chen

Rogelio Siles

Charles Rudolph

Marc W Weimer

Kyle A Totaro

Inserts can be formed with elution characteristics to cause the inserts to elute an antimicrobial agent when subject to a fluid within a medical device. An insert can be formed with a desired geometry to allow the insert to be compression fit within a medical device to prevent the insert from moving or becoming dislodged once inserted into the medical device. The material may also be hygroscopic so that the insert swells when subject to a fluid thereby enhancing the compression fit of the device within the medical device. In some cases, the material can be reinforced using an internal structure. Inserts can be formed in many ways including by casting, thermoforming, or extrusion. In some cases, the inserts can be formed using a peel-away sleeve or material. The peel-away sleeves can be formed of a non-sticky material which facilitates removal of the inserts once the inserts have cured.

Antimicrobial inserts for medical devices

Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.

Peptide oligonucleotide conjugates

Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3' and/or 5&#x2032;-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Functionally-modified oligonucleotides and subunits thereof

Principles and embodiments of the present invention relate generally to thermoplastic polyurethane materials having controlled and improved stiffness and/or flexibility, and methods to prepare them. The thermoplastic polyurethanes described herein having superior stiffness and softening properties may be fabricated into film, tubing, and other forms of medical devices. The thermoplastic polyurethanes comprise: an aromatic diisocyanate excluding non-aromatic diisocyanates; at least one polyglycol; and a chain extender comprising at least one side-chain branching diol and excluding linear diols.

Thermoplastic polyurethane materials for forming medical devices

Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3' and/or 5&#x2032;-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

Catheters, vascular access devices using such catheters, methods of using such catheters and uses of such catheters are disclosed. The catheter comprises polymeric tubing including a composition that can be magnetized by application of an externally applied magnetic field, thereby magnetizing the tubing. Detection of the magnetic field provides location information for the catheter in the vasculature.

Magnetized catheters, devices, uses and methods of using magnetized catheters

Oligonucleotide analogs comprising modified intersubunit linkages and/or modified 3' and/or 5&#x2032;-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Growing community of inventors

Coppell, TX, United States of America

Ming Zhou